BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...anti-ICOSL mAb. Alpine presented the data last year at the American Society of Rheumatology meeting. Dapirolizumab pegol...
BioCentury | Dec 3, 2019
Clinical News

Biogen plotting next steps in lupus after latest readout

..."Hills to Climb" ; "Ehlers Exits" ). BIIB059 sits just behind another lupus candidate, dapirolizumab pegol...
...BIIB059, which is wholly-owned, dapirolizumab pegol is partnered with UCB S.A. (Euronext:UCB). Batchelder said BIIB059 and dapirolizumab pegol...
BioCentury | Sep 18, 2019
Distillery Therapeutics

Preventing glial cell graft rejection with a T cell-targeting immunotherapy

...of demyelination. At least three anti-CD40L antibody-based therapies are in the clinic. The most advanced, dapirolizumab pegol...
BioCentury | Jul 23, 2019
Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

...systemic lupus erythematosus (SLE); it intends to start a Phase III trial next half of dapirolizumab pegol...
...motor neuron 2 centromeric Consensus figures provided by FactSet. Paul Bonanos, Associate Editor Anti-CD40L Fab, dapirolizumab pegol (CD40L, CDP7657) BIIB059 NSR-REP1...
BioCentury | Jan 26, 2019
Product Development

Target wide, test narrow in lupus

...LOI) vs. placebo (42% vs. 28.6%, p=0.18) Oct. 23rd Biogen Inc. (NASDAQ:BIIB); UCB S.A. (Euronext:UCB) Dapirolizumab pegol...
...CD80 and CD86, preventing their interaction with the T cell costimulatory receptor CD28. Pegylated Fab dapirolizumab pegol...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Transplant

...models of antibody-mediated lung transplant rejection. Biogen Inc., Nektar Therapeutics Inc. and UCB S.A. have dapirolizumab pegol...
BioCentury | Oct 26, 2018
Clinical News

Biogen, UCB report Phase IIb miss for lupus candidate dapirolizumab

...Biogen Inc. (NASDAQ:BIIB) and UCB S.A. (Euronext:UCB) reported top-line data showing dapirolizumab pegol missed the primary endpoint...
..."Rebuilding Biogen's Brain" ). Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. UCB S.A. (Euronext:UCB), Brussels, Belgium Product: Dapirolizumab pegol...
...Inventory (BPI)-Interference and BPI-Pain index Status: Phase IIb data Milestone: NA Jennie Walters Anti-CD40L Fab, dapirolizumab pegol (CD40L, CDP7657) raxatrigine...
BioCentury | Oct 23, 2018
Company News

Biogen halts vixotrigine development in painful lumbosacral radiculopathy

...II Alzheimer's Trial" ). Separately Tuesday, Biogen and UCB S.A. (Euronext:UCB) reported top-line data showing dapirolizumab pegol...
BioCentury | Nov 11, 2013
Clinical News

Anti-CD40L Fab: Phase Ib started

...Ib trial to evaluate CDP7657 in patients with SLE. Biogen Idec and UCB are co-developing CDP7657...
...Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. UCB Group (Euronext:UCB), Brussels, Belgium Product: Anti-CD40L Fab ( CDP7657...
BioCentury | Jan 2, 2012
Company News

Biogen Idec, UCB, ALS TDI deal

...with Biogen Idec and UCB, the not-for-profit institute will conduct preclinical testing of the companies' CDP7657...
...to develop and commercialize compounds targeting the CD40L pathway in ALS. The companies are co-developing CDP7657...
Items per page:
1 - 10 of 14